Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm.
Similar Posts
MHRA statement on the PATHWAYS puberty blocker trial
With all complex clinical trials, MHRA’s top priority is the safety and wellbeing of the trial participants
Supplying authorised medicines to Northern Ireland
What you need to do to supply authorised medicines from Great Britain to Northern Ireland.
Form: Medicines marketing authorisation: change of ownership application
Use this form to transfer a product licence, also known as a marketing authorisation, to a different owner.
Guidance: Report on Adverse Event (AE) reporting in digital mental health technologies (DMHTs) and the development of updates to regulatory guidance
Advice for manufacturers of DMHTs that qualify as software as a medical device (SaMD) on understanding new post marketing surveillance rules and examples of how they apply.
MHRA updates guidance on the Health Institution Exemption to support safe use of medical devices
Updated MHRA guidance will help health institutions, such as NHS Trusts and Boards, safely design and make general medical devices for patients.
Class 2 Medicines Recall: Fucidin 250 mg Tablets, LEO Laboratories Ltd trading as LEO Pharma, EL(25)A/38
LEO Pharma is recalling the affected batch as a precautionary measure due to out of specification results for impurities during routine stability testing.